TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer

Figure 2

Objective response rate (ORR) and disease control rate (DCR) of TAS-102 monotherapy or combination therapy with bevacizumab for metastatic colorectal cancer.